Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer - Jazz Pharmaceuticals ( NASDAQ:JAZZ )

4 weeks ago

Jazz Pharmaceuticals plc JAZZ revealed topline results from the Phase 3 clinical trial evaluating Zepzelca ( lurbinectedin ) in combination with the PD-L1 inhibitor Roche Holdings AG's RHHBY atezolizumab ( Tecentriq ) compared to atezolizumab alone when administered as a maintenance treatment ...

Ticker	Sentiment	Impact
JAZZ	Somewhat Bearish	49 %